297 related articles for article (PubMed ID: 25274276)
1. SEOM clinical guidelines for the treatment of renal cell carcinoma.
Bellmunt J; Puente J; Garcia de Muro J; Lainez N; Rodríguez C; Duran I;
Clin Transl Oncol; 2014 Dec; 16(12):1043-50. PubMed ID: 25274276
[TBL] [Abstract][Full Text] [Related]
2. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
3. SEOM clinical guideline for treatment of kidney cancer (2017).
Gallardo E; Méndez-Vidal MJ; Pérez-Gracia JL; Sepúlveda-Sánchez JM; Campayo M; Chirivella-González I; García-Del-Muro X; González-Del-Alba A; Grande E; Suárez C
Clin Transl Oncol; 2018 Jan; 20(1):47-56. PubMed ID: 29134564
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
7. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer.
Bigot P; Barthelemy P; Boissier R; Khene ZE; Pettenati C; Bernhard JC; Correas JM; Doumerc N; Gimel P; Ingels A; Nouhaud FX; Ouzaïd I; Rioux-Leclercq N; Albiges L; Rouprêt M
Prog Urol; 2022 Nov; 32(15):1195-1274. PubMed ID: 36400482
[TBL] [Abstract][Full Text] [Related]
8. Current management and future perspectives of metastatic renal cell carcinoma.
Lee-Ying R; Lester R; Heng D
Int J Urol; 2014 Sep; 21(9):847-55. PubMed ID: 24862210
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cell carcinoma.
Sun M; Lughezzani G; Perrotte P; Karakiewicz PI
Nat Rev Urol; 2010 Jun; 7(6):327-38. PubMed ID: 20458330
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted therapy for advanced renal carcinoma: trials in progress.
Calabrò F; Sternberg CN
Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
[TBL] [Abstract][Full Text] [Related]
11. [New trends in the diagnosis and treatment of renal cell carcinoma].
Zisman A
Harefuah; 2002 Aug; 141(8):713-7, 761. PubMed ID: 12222136
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Pal SK; Signorovitch JE; Li N; Zichlin ML; Liu Z; Ghate SR; Perez JR; Vogelzang NJ
Int J Urol; 2017 Apr; 24(4):272-278. PubMed ID: 28253548
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
15. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
17. [Systemic and surgical management of metastatic renal cell carcinoma].
Kramer MW; Merseburger AS; Peters I; Waalkes S; Kuczyk MA
Urologe A; 2012 Feb; 51(2):217-25. PubMed ID: 22009257
[TBL] [Abstract][Full Text] [Related]
18. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma in children and adolescents.
Spreafico F; Collini P; Terenziani M; Marchianò A; Piva L
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1967-78. PubMed ID: 21110762
[TBL] [Abstract][Full Text] [Related]
20. [Renal cell carcinoma: Drug therapy and prognostic models].
Reiter MA; Kurosch M; Haferkamp A
Urologe A; 2015 May; 54(5):735-46; quiz 747-8. PubMed ID: 25987339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
